Tier 2 — strong

Two-month period of 500 mg lecithin-based delivery form of quercetin daily dietary supplementation counterbalances chronic fatigue symptoms: A double-blind placebo controlled clinical trial

Mariangela Rondanelli, Antonella Riva, Giovanna Petrangolini, Clara Gasparri, Simone Perna
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 2023 167:115453

Bibliography

PubMed
PMID 37716119
DOI
10.1016/j.biopha.2023.115453
Funding
Funding was not specified in the indexed record or the disclosure metadata available for this entry.
Competing interests
Reported disclosure: AR and GP are employed by Indena SpA. The remaining authors declare no conflict of interest.

Study snapshot

DesignDouble-blind placebo-controlled clinical trial
ModelHuman intervention research
Sample78 adults with chronic-fatigue symptoms completed: 40 supplement and 38 placebo
InterventionLecithin-based Quercetin Phytosome formulation 500 mg/day
Duration2 months
EndpointsCognitive, mood, or sleep measures

What the study showed, in plain terms

Published in 2023, this source examined brain, cognition and sleep. Design: Double-blind placebo-controlled clinical trial. Sample/model: 78 adults with chronic-fatigue symptoms completed: 40 supplement and 38 placebo. The exposure or intervention was Lecithin-based Quercetin Phytosome formulation 500 mg/day. Follow-up or treatment period: 2 months.

Fatigue and sleep scores, step counts and a physical-performance measure favored the supplement.

Product-specific short-term study of symptom-defined fatigue. Formulation mass is not interchangeable with pure quercetin dose or evidence for every fatigue disorder.

Continue with Quercetin Data Center

For topic-level interpretation, read Quercetin for Brain Fog, Memory and Sleep: Human Evidence. This is a related guide; the citation panel separately identifies articles that directly cite this paper.

Key findings

  • Fatigue and sleep scores, step counts and a physical-performance measure favored the supplement.
  • The recorded outcome domains were Cognitive, mood, or sleep measures.
  • The result applies to the tested exposure: Lecithin-based Quercetin Phytosome formulation 500 mg/day; 2 months.

What this study can and cannot tell us

  • Product-specific short-term study of symptom-defined fatigue. Formulation mass is not interchangeable with pure quercetin dose or evidence for every fatigue disorder.
  • An individual controlled trial must be interpreted alongside its comparator, sample size, endpoint selection and independent replication. It does not validate a different commercial formulation or a general longevity claim.
  • Source basis: Source check: PubMed abstract and indexed metadata; full methods were not independently confirmed for this entry. Missing method details, funding information or participant denominators are not inferred.

Related papers in the corpus

Tier 2
Assessment of the Efficacy of Quercetin in Adult Patients With Autism Spectrum Disorder: A Randomized, Triple-Blind, Placebo-Controlled Trial
Anahid Rezaeifar et al. · Human psychopharmacology · 2026
Tier 2
Memory-Enhancing Effect of 8-Week Consumption of the Quercetin-Enriched Culinary Herbs-Derived Functional Ingredients: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
Jintanaporn Wattanathorn et al. · Foods (Basel, Switzerland) · 2022
Tier 2
Effect of quercetin glycosides on cognitive functions and cerebral blood flow: a randomized, double-blind, and placebo-controlled study
Y Nakamura et al. · European review for medical and pharmacological sciences · 2022

Citation network

Articles citing this research paper

2 articles

Biohack Blueprint analyses that reference this study in their evidence base.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology